Share Price | Compass Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Compass Therapeutics, Inc. do?

Overview:Compass Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025)Market cap: USD 302.84 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.02Return on Equity: -50.07%Price to Book: 2.75Contact Details:Details: No Company Details AvailableRegistrar Address: Not available.

Q: Is Compass Therapeutics, Inc. technically bullish or bearish?

As of 11 August 2025, the technical trend for Compass Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also reflect a bullish stance across both time frames. Daily moving averages are bullish, while the KST indicators are bullish on both weekly and monthly charts. Dow Theory shows a mildly bullish trend on both weekly and monthly bases. The RSI does not provide a signal in either time frame, and OBV is mildly bullish weekly but shows no trend monthly.The company has significantly outperformed the S&P 500, with a year-to-date return of 153.79% compared to the S&P 500's 12.22%, and a one-year return of 125.77% versus 17.14% for the benchmark. Overall, the current technical stance is bullish with strong indicators supporting this view.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.01 M

Shareholding (Sep 2025)

FII

3.15%

Held by 34 FIIs

DII

67.21%

Held by 22 DIIs

Promoter

20.09%

How big is Compass Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Compass Therapeutics, Inc. has a market capitalization of 302.84 million and reported net sales of 0.85 million with a net loss of 55.22 million over the last four quarters.

View full answer

What does Compass Therapeutics, Inc. do?

22-Jun-2025

Compass Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $17 million and a market cap of $302.84 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -50.07%.

View full answer

Is Compass Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 11, 2025, Compass Therapeutics, Inc. shows a bullish technical trend with strong indicators across multiple time frames, significantly outperforming the S&P 500 with a year-to-date return of 153.79%.

View full answer

Compare Compass Therapeutics, Inc. with Similar Stocks

Lexicon Pharmaceuticals, Inc.Atea Pharmaceuticals, Inc.Ovid Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,049 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.05

Return on Equity

-31.39%

Price to Book

5.01

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-14 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

63.0%

6 Months

124.05%

1 Year

86.29%

2 Years

379.41%

3 Years

65.48%

4 Years

260.22%

5 Years

0.0%

Compass Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-191.48%

EBIT to Interest (avg)

-43.58

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

71.07%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.13

EV to EBIT

-3.77

EV to EBITDA

-3.88

EV to Capital Employed

-103.77

EV to Sales

233.18

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-50.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 27 Schemes (9.55%)

Foreign Institutions

Held by 34 Foreign Institutions (3.15%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -36.19% vs -5.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.40",
          "val2": "-11.80",
          "chgp": "-30.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.30",
          "val2": "-10.50",
          "chgp": "-36.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -16.24% vs -8.42% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.90",
          "val2": "-48.50",
          "chgp": "-13.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.40",
          "val2": "-42.50",
          "chgp": "-16.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-66,617.60%",
          "val2": "0.00%",
          "chgp": "-6,661.76%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-15.40

-11.80

-30.51%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.30

-10.50

-36.19%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -36.19% vs -5.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.80

0.00

Operating Profit (PBDIT) excl Other Income

-54.90

-48.50

-13.20%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-49.40

-42.50

-16.24%

Operating Profit Margin (Excl OI)

-66,617.60%

0.00%

-6,661.76%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -16.24% vs -8.42% in Dec 2023

All Annual Results

Company CV

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Compass Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Compass Therapeutics, Inc.?

Watch in Real-Time

What does Compass Therapeutics, Inc. do?

Is Compass Therapeutics, Inc. technically bullish or bearish?

Compare Compass Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Compass Therapeutics, Inc.

Company Coordinates